東山精密(002384.SZ):終止分拆艾福電子至創業板上市
格隆匯2月18日丨東山精密(002384.SZ)公佈,公司於2022年2月17日召開的第五屆董事會第十九次會議、第五屆監事會第十三次會議審議通過《關於終止控股子公司分拆至創業板上市的議案》,此次終止分拆事項尚需公司股東大會審議通過。
自籌劃本次分拆上市事項以來,公司積極推進相關事宜,組織中介機構開展盡職調查等相關工作。但因5G基站建設進度低於預期,市場競爭加劇,且艾福電子的客户和產品較為集中,導致其經營業績不達預期。經充分審慎的研究,公司認為現階段繼續推進艾福電子分拆上市的條件不成熟,決定終止本次分拆上市事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.